401
Participants
Start Date
December 21, 2018
Primary Completion Date
January 11, 2021
Study Completion Date
September 27, 2026
Durvalumab
Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
Placebo for Olaparib
Matching tablet
Olaparib
150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
Nab-paclitaxel+carboplatin
Standard of Care chemotherapy (squamous and non-squamous patients)
Gemcitabine+carboplatin
Standard of Care chemotherapy (squamous patients only)
Pemetrexed+carboplatin
Standard of Care chemotherapy (non-squamous patients only)
Gemcitabine+cisplatin
Standard of Care chemotherapy (squamous patients only)
Pemetrexed+cisplatin
Standard of Care chemotherapy (non-squamous patients only)
Research Site, Budapest
Research Site, Budapest
Research Site, Blaricum
Research Site, Törökbálint
Research Site, Leuven
Research Site, Harderwijk
Research Site, Debrecen
Research Site, Deszk
Research Site, Farkasgyepü
Research Site, Roeselare
Research Site, Aalst
Research Site, Goyang-si
Research Site, Suweonsi Paldalgu
Research Site, Bethlehem
Research Site, Kirovohrad
Research Site, Chihuahua City
Research Site, West Palm Beach
Research Site, St. Petersburg
Research Site, Bonita Springs
Research Site, Nashville
Research Site, Chattanooga
Research Site, Dnipro
Research Site, Kharkiv Region
Research Site, Kansas City
Research Site, Odesa
Research Site, Zaporizhzhia
Research Site, Houston
Research Site, San Luis Potosí City
Research Site, Culiacán
Research Site, Uzhhorod
Research Site, Moscow
Research Site, P. Herzen Moscow Oncology Rese
Research Site, Yaroslavl
Research Site, Arkhangelsk
Research Site, Saint Petersburg
Research Site, Kursk
Research Site, Sochi
Research Site, Nal'chik
Research Site, Jamnagar
Research Site, Ahmedabad
Research Site, Ahmedabad
Research Site, Pune
Research Site, Nashik
Research Site, Nashik
Research Site, Nashik
Research Site, Chelyabinsk
Research Site, Mysuru
Research Site, Kochi
Research Site, Thiruvananthapuram
Research Site, Tallahassee
Research Site, Chūōku
Research Site, Kanazawa
Research Site, Kurume-shi,
Research Site, Matsuyama
Research Site, Nagoya
Research Site, Sendai
Research Site, Sunto-gun
Research Site, Ube-shi
Research Site, Tilburg
Research Site, Bialystok
Research Site, Lodz
Research Site, Poznan
Research Site, Prabuty
Research Site, Dongjakgu
Research Site, Seodaemun-gu
Research Site, Seoul
Research Site, Seoul
Research Site, Dundee
Research Site, Hull
Lead Sponsor
AstraZeneca
INDUSTRY